Capricor Therapeutics's Earnings Outlook
Portfolio Pulse from Benzinga Insights
Capricor Therapeutics (NASDAQ:CAPR) is expected to report a Q4 earnings per share (EPS) of $-0.09 on Thursday, 2024-02-29. Analysts and investors are looking for an earnings beat and positive guidance for the next quarter. Historically, Capricor has had mixed earnings performance, with share price reactions varying post-earnings announcement. Currently, shares are trading at $4.34, down 13.85% over the last 52 weeks.
February 28, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Capricor Therapeutics is anticipated to report a Q4 EPS of $-0.09, with investors hoping for an earnings beat and positive future guidance. Shares have declined 13.85% over the past year.
Given Capricor's history of mixed earnings performance and the potential for an earnings beat and positive guidance, there is a cautiously optimistic outlook for the short-term impact on CAPR's stock price. The historical data shows that positive earnings surprises have led to share price increases, suggesting a potential positive short-term impact if the company beats the EPS estimate and provides favorable future guidance.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100